

FOI 2937

14th February 2025**FREEDOM OF INFORMATION ACT 2000 – INFORMATION REQUEST****Question 1:**

Does your trust provide SACT (systemic anti-cancer therapy) treatments for Renal Cell Carcinoma? If not, which other trust do you refer Renal Cell Carcinoma patients to for SACT treatments?

Response:

This information may be held by the Belfast Health & Social Care Trust.

You can contact them at:

<https://belfasttrust.hscni.net/about/access-to-information/foi/>

Question 2:

How many patients have been treated in the past 3 months with the following agents for renal cell carcinoma (any stage):

- **Avelumab + Axitinib**
- **Axinitib**
- **Cabozantinib**
- **Everolimus**
- **Lenvatinib + Everolimus**
- **Lenvatinib + Pembrolizumab**
- **Nivolumab monotherapy**
- **Nivolumab + Cabozantinib**
- **Nivolumab + Ipilimumab**
- **Pazopanib**
- **Pembrolizumab monotherapy**
- **Pembrolizumab + Axitinib**
- **Radiotherapy only**
- **Sunitinib**
- **Temsirolimus**
- **Tivozanib**
- **Other active systemic anti-cancer therapy**
- **Palliative care only**

Response:

This information may be held by the Belfast Health & Social Care Trust.

You can contact them at:

<https://belfasttrust.hscni.net/about/access-to-information/foi/>

Email: Foi.Team@Southerntrust.hscni.net